PCRX vs XOMA
PCRX: Pacira BioSciences is a non-opioid pain management company commercializing injectable, device, and gene therapy treatments for postsurgical and osteoarthritis pain. XOMA: A lean-infrastructure royalty aggregator that generates non-dilutive capital for biotech developers in exchange for long-duration milestone and royalty rights across a diversified 120+ asset portfolio spanning oncology, rare disease, and specialty therapeutics.
Side-by-side fundamentals
| Metric | PCRX | XOMA | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $26.47 | $40.17 | |
| Market cap as of 2026-07-30 | $1.0B | $504M | |
| P/E as of 2026-07-30 | 203.64 | 21.00 | XOMA lower |
| PEG as of 2026-07-30 | 17.75 | n/a | |
| Net margin as of 2026-07-30 | +0.7% | +69.6% | XOMA higher |
| Gross margin as of 2026-07-30 | +79.3% | +100.0% | XOMA higher |
| Operating margin as of 2026-07-30 | +0.1% | +61.3% | XOMA higher |
| ROE as of 2026-07-30 | +0.7% | +32.4% | XOMA higher |
| ROA as of 2026-07-30 | +0.4% | +13.1% | XOMA higher |
| Debt / equity as of 2026-07-30 | 0.56 | 0.91 | PCRX lower |
| Revenue growth (YoY) as of 2026-07-30 | +4.6% | +13.2% | XOMA higher |
| Revenue CAGR (3y) SEC XBRL | +2.9% | +105.3% | XOMA higher |
| Dividend yield as of 2026-07-30 | n/a | +0.8% | |
| Beta as of 2026-07-30 | 0.25 | 0.88 | |
| 1-year return as of 2026-07-27 close | +17.4% | +57.7% | XOMA higher |
Fundamentals: market data, as of 2026-07-30. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.